ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

NCI’s Drug Screen Tests 400 Agents A Week; Recompetition Of Contracts Approved

February 26, 1993

In Brief: Registration Deadlines Coming Up For 13th Cancer Congress; Breast Cancer Meeting Postponed To ‘83

May 28, 1982

NCAB Seeks Greater flexibility In Grants Target To Aid P01s

May 31, 1991

Wanted: Methods To Measure Or Estimate Renal Function For Dosing Cancer Drugs

October 15, 2010

Gallo Actively Searching For New Position

July 1, 1994

BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women

November 3, 1978